Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





VANADIUM PENTOXIDE FUME								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 1314-62-1; **Chemical Formula:** V2O5
OSHA’s former PEL for vanadium pentoxide fume was 0.1 mg/m3 as a ceiling limit. The Agency proposed to revise this limit to 0.05 mg/m3 as an 8-hour TWA, based on the ACGIH recommendation. OSHA is establishing this limit in the final rule.
Vanadium pentoxide fume’s chief toxic effects are manifested in the respiratory passages: bronchitis, emphysema, tracheitis, pulmonary edema, and bronchial pneumonia can result from exposure. According to Hudson (1964/Ex. 1-880), vanadium is poisonous to all animals by all routes of administration. The LD(50) in rabbits injected intravenously is 1.5 mg/kg, and rats fed 25 ppm demonstrated toxic responses within a short time (Hudson 1964/Ex. 1-880).
Seven cases of upper respiratory tract irritation were reported in boiler cleaners exposed to concentrations of from 2 to 85 mg/m3 vanadium pentoxide fume (Sjoberg 1951/Ex. 1-437). Williams (1952/Ex. 1-456) reported eight cases of vanadium poisoning in workers cleaning boilers in an atmosphere ranging from 30 to 104 mg/m3. Gul’ko (1956, as cited by Hudson 1964/Ex. 1-880) observed eye and bronchial irritation in workers exposed to 0.5 to 2.2 mg/m3. A study by Lewis (1959/Ex. 1-345) indicated that workers exposed to levels of 0.2 to 0.5 mg/m3 experienced a higher incidence of respiratory symptoms than did controls. Tebrock and Machle (1968/Ex. 1-446) reported that workers exposed to average concentrations of 1.5 mg/m3 vanadium pentoxide in a mixed dust developed conjunctivitis, tracheobronchitis, and dermatitis. A single average eight-hour exposure to 0.2 mg/m3 respirable vanadium dust caused severe upper respiratory tract irritation in five human volunteers, and two other subjects exposed to a 0.1-mg/m3 concentration also developed delayed cough and an increase in mucous production (Zenz and Berg 1967/Ex. 1-405).
NIOSH (Ex. 8-47, Table N7) recommended a 15-minute ceiling limit of 0.05 mg/m3 for vanadium fume as vanadium pentoxide. However, OSHA is concerned about cumulative exposures below the former 0.1 mg/m3 ceiling, and the Agency concludes that the TWA limit originally proposed will protect workers from the significant risks of eye, skin, and upper respiratory tract irritation; conjunctivitis; pulmonary damage; and systemic poisoning associated with exposure to vanadium pentoxide fume at even brief excursions to higher levels. The Agency considers these irritant and systemic effects to be material impairments of health. Accordingly, OSHA is establishing a PEL of 0.05 mg/m3 as an 8-hour TWA for this substance in today’s rule.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue